Literature DB >> 29958128

Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Zoe M Weinstein1, Gabriela Gryczynski2, Debbie M Cheng3, Emily Quinn4, David Hui5, Hyunjoong W Kim5, Colleen Labelle6, Jeffrey H Samet7.   

Abstract

BACKGROUND: Guidelines recommend long-term treatment for opioid use disorder including the use of buprenorphine; however, many patients desire to eventually taper off. This study examines the prevalence and patient characteristics of patients that voluntarily taper off buprenorphine.
METHODS: This is a 12-year retrospective cohort study of adults on buprenorphine in a large urban safety-net primary care practice. The primary outcome was completion of a voluntary buprenorphine taper, which was further characterized as a medically supervised or unsupervised taper. The secondary outcome was re-engagement in care after taper. Descriptive statistics and estimated proportions of both taper completion and re-engagement in treatment were calculated using Kaplan-Meier estimates.
RESULTS: The study sample included 1308 patients with a median follow-up time of 316 days; 48 patients were observed to taper off buprenorphine during the study period, with an estimated proportion of 15% (95%CI: 10%-21%) based on Kaplan Meier analyses. Less than half of the tapers, 45.8% (22/48), were medically supervised. Thirteen of the 48 patients subsequently, re-engaged in buprenorphine treatment (estimated proportion 61%, 95%CI: 27%-96%), based on Kaplan-Meier analyses with median follow-up time of 490 days. DISCUSSION: Despite the fact that many patients desire to discontinue buprenorphine, a minority had a documented taper. Among those who tapered, more than half did so unsupervised by the clinic and a majority of those who tapered off returned to buprenorphine treatment within two years. As many patients are unable to successfully taper off buprenorphine, the medical community must work to address any barriers to long-term maintenance.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Opioid use disorder; Patient dropout

Mesh:

Substances:

Year:  2018        PMID: 29958128      PMCID: PMC6139651          DOI: 10.1016/j.drugalcdep.2018.05.010

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  30 in total

Review 1.  Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored.

Authors:  S Magura; A Rosenblum
Journal:  Mt Sinai J Med       Date:  2001-01

2.  Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study.

Authors:  Bohdan Nosyk; Huiying Sun; Elizabeth Evans; David C Marsh; M Douglas Anglin; Yih-Ing Hser; Aslam H Anis
Journal:  Addiction       Date:  2012-05-08       Impact factor: 6.526

3.  Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Authors:  Bruce R Schackman; Jared A Leff; Daniel Polsky; Brent A Moore; David A Fiellin
Journal:  J Gen Intern Med       Date:  2012-01-04       Impact factor: 5.128

4.  Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial.

Authors:  Elias Dakwar; Herbert D Kleber
Journal:  J Subst Abuse Treat       Date:  2015-01-15

5.  Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.

Authors:  Mark L Kraus; Daniel P Alford; Margaret M Kotz; Petros Levounis; Todd W Mandell; Marjorie Meyer; Edwin A Salsitz; Norman Wetterau; Stephen A Wyatt
Journal:  J Addict Med       Date:  2011-12       Impact factor: 3.702

6.  A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.

Authors:  Stacey C Sigmon; Kelly E Dunn; Kathryn Saulsgiver; Mollie E Patrick; Gary J Badger; Sarah H Heil; John R Brooklyn; Stephen T Higgins
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

7.  A Case of Opioid Overdose and Subsequent Death After Medically Supervised Withdrawal: The Problematic Role of Rapid Tapers for Opioid Use Disorder.

Authors:  Derek C Chang; Jan Klimas; Evan Wood; Nadia Fairbairn
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

Review 8.  Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.

Authors:  Laura Amato; Silvia Minozzi; Marina Davoli; Simona Vecchi
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

Review 9.  Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.

Authors:  Brandon S Bentzley; Kelly S Barth; Sudie E Back; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2014-12-30

10.  Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathi Peindl; David A Gorelick; Li-Tzy Wu; Edward Gottheil
Journal:  Addict Biol       Date:  2008-08-19       Impact factor: 4.280

View more
  5 in total

1.  Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.

Authors:  Michael D Stein; Micah T Conti; Debra S Herman; Bradley J Anderson; Genie L Bailey; Donnell Van Noppen; Ana M Abrantes
Journal:  Am J Addict       Date:  2019-04-16

2.  Age-based preferences for risk communication in the fentanyl era: 'A lot of people keep seeing other people die and that's not enough for them'.

Authors:  Christine M Gunn; Ariel Maschke; Miriam Harris; Samantha F Schoenberger; Spoorthi Sampath; Alexander Y Walley; Sarah M Bagley
Journal:  Addiction       Date:  2020-11-26       Impact factor: 6.526

3.  Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.

Authors:  Nikki Bozinoff; Siyu Men; Paul Kurdyak; Peter Selby; Tara Gomes
Journal:  JAMA Netw Open       Date:  2022-09-01

4.  A Research Agenda for Advancing Strategies to Improve Opioid Safety: Findings from a VHA State of the Art Conference.

Authors:  William C Becker; Erin E Krebs; Sara N Edmond; Lewei A Lin; Mark D Sullivan; Roger D Weiss; Adam J Gordon
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

5.  Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.

Authors:  Sandra D Comer; Paolo Mannelli; Danesh Alam; Antoine Douaihy; Narinder Nangia; Sarah C Akerman; Abigail Zavod; Bernard L Silverman; Maria A Sullivan
Journal:  Am J Addict       Date:  2020-04-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.